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Background. Masked uncontrolled hypertension (MUCH) is associated with an 
increased cardiovascular risk. This condition is frequent in the community 
pharmacy (CP-MUCH), but there is no evidence on the factors associated to its 
presence in that setting. The aim of this analysis was to explore those factors. 
Methods. A sample of 98 treated hypertensive patients from the MEPAFAR 
study, with normal community pharmacy blood pressure (CPBP <135/85 
mmHg), were analyzed. BP was also measured at home (4 days) and 
monitored for 24-hour. CP-MUCH was identified when either ambulatory 
(daytime) or home BP averages were ≥135/85 mmHg. A multivariate logistic 
regression analysis was performed to identify the factors associated with CP-
MUCH. Results. The prevalence CP-MUCH tends to be higher as systolic and 
diastolic CPBP increases, reaching 47% in patients with both systolic CPBP 
≥123 mmHg and diastolic CPBP ≥79 mmHg. The multivariate regression 
analysis revealed only systolic CPBP as an independent factor of CP-MUCH 
[≥123 mmHg: OR=16.46 (p=0.012); from 115 to 122.9 mmHg: OR=10.74 
(p=0.036); systolic CPBP <115 mmHg as the reference]. Conclusion. Further 
assessment, using ambulatory and/or home BP monitoring, is recommended in 
patients with normal CPBP, but systolic CPBP ≥115 mmHg. A more feasible 
approach would be evaluating patients with both systolic CPBP ≥123 mmHg 
and diastolic CPBP ≥79 mmHg. 





Masked uncontrolled hypertension (MUCH) is defined in those treated 
hypertensive patients who have elevated ambulatory (ABP) or home blood 
pressure (HBP) despite normal physician office measurements1. This condition 
is found in 22% of treated patients and has been associated with an increased 
cardiovascular risk2. This higher risk may be explained by the fact that ABP and 
HBP have been shown to be stronger predictors of target organ damage and 
cardiovascular events than blood pressure measured in a physician’s office 
(BP)3,4. 
MUCH could remain undetected if only office BP readings are available for 
evaluation. As a consequence, if normal BP figures are measured in the 
physician’s office, the necessary adjustments in treatment may not be made 
and the underlying risk associated with elevated ABP or HBP would therefore 
not be well managed. As measuring out-of-office BP in all normotensive 
individuals is not a feasible or efficient strategy in daily clinical practice, several 
studies have been carried out to identify the factors associated with the 
presence of MUCH5-9. By considering these factors and identifying patients who 
are more likely to have MUCH, a further assessment, using ABP or HBP 
monitoring, could be recommended.  
MUCH has also been identified as a relatively frequent condition in the 
community pharmacy (CP-MUCH)10,11. Particularly in this case, if normal BP 
figures are measured in the community pharmacy, pharmacists would not refer 
patients to a physician, and again, the necessary changes in treatment would 
not be made. Given that CP-MUCH could influence both decision-making 
5 
 
processes and health outcomes, the presence of this condition should be 
carefully investigated when pharmacists deliver pharmaceutical care services to 
treated hypertensive patients. 
To our knowledge, there are no reports in the literature on the factors 
associated with CP-MUCH. As a consequence, community pharmacists do not 
have guidelines which would allow them to better identify patients who are likely 
to present with CP-MUCH. In light the prevalence of CP-MUCH and given its 
clinical implications, a subgroup analysis of patients with normal community 
pharmacy BP (CPBP) who were included in the MEPAFAR study11 was carried 
out to explore the factors associated with CP-MUCH. 
Methods 
The MEdida de la Presión Arterial en FARmacia (MEPAFAR) study was a 
cross-sectional study, conducted from June 2008 to June 2009 in 8 Spanish 
community pharmacies. The main aim of the study was to assess the 
agreement between CPBP, daytime ABP, and HBP in treated hypertensive 
patients11 and so, the capacity of the CPBP measurement method to evaluate 
the effectiveness of antihypertensive treatment. The protocol of the MEPAFAR 
study was assessed and approved by the Research Ethics Committee of the 
University of Granada (Spain). 
BP measurements methods have been comprehensively described in previous 
publications11,12. Briefly, CPBP was measured at 4 visits, by the same 
pharmacist at each pharmacy, over a 4-week period. At each visit, 3 BP 
measurements were taken (2-3 minutes apart) on the control arm (arm on which 
CPBP was higher on the first visit). Patients’ visits to the pharmacy were 
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scheduled at the same time for all 4 time points (± 1 hour). Mean CPBP was 
calculated discarding the data from the first visit and the first measurement from 
each visit. For the purpose of this sub-analysis, normal CPBP was defined by 
systolic BP (SBP) <135 mmHg and diastolic BP (DBP) <85 mmHg. 
At home, patients monitored their BP over 4 consecutive working days, taking 3 
measurements in the morning (2 minutes apart, 6am to 9am) and 3 
measurements in the evening (6pm to 9pm) on the non-dominant arm. HBP 
readings were stored in the device’s memory. Mean HBP was calculated, 
discarding values obtained on the first day and using the first and second 
measure from each morning and each evening. Normal HBP was defined by 
SBP <135 mmHg and DBP <85 mmHg. The clinically validated OMRON M10-IT 
automatic electronic device (Omron Corp, Tokyo, Japan)13 was used both at 
home and in the community pharmacy. 
ABPM was performed on a working day (24 hours), using the non-dominant 
arm. Measurements were taken every 20minutes (7am to 10pm) or 30 minutes 
(10pm to 7am). The clinically validated Spacelabs Medical 90207-5Q monitor 
(Spacelabs Inc., Redmond, WA) was used14. Average daytime ABP was 
calculated according to a sleep diary kept by each patient. Normal daytime ABP 
was defined by SBP <135 mmHg and DBP <85 mmHg. 
Based on recent acknowledged definitions15,16, CP-MUCH was defined when an 
average CPBP (SBP/DBP) of <135/85 mmHg was combined with one or both of 




To characterize the study sample, the following variables were collected: age, 
gender, smoking status, body mass index (BMI), number of antihypertensive 
drugs used, adherence to antihypertensive drugs (Morisky-Green test17), history 
of previous cardiovascular disease (stroke, myocardial infarction, angina, or 
peripheral artery disease), and presence of diabetes or dyslipidemia 
(documented diagnosis or previously prescribed drug treatment). 
Statistical analysis. SPSS version 15.0 (SPSS Inc., Chicago, IL, USA) was used 
for the statistical calculations. Mean and standard deviation (SD) were used to 
summarize quantitative variables. Qualitative variables were described using 
frequencies and percentages. To compare the quantitative variables, Student’s t 
test for independent samples was used. Differences between CPBP, HBP, and 
daytime ABP were assessed by repeated measures analysis of variance, 
applying the Bonferroni correction. Chi-square and Fisher’s exact tests were 
performed for comparisons of proportions. 
To identify the independent factors associated with CP-MUCH a multivariate 
logistic regression analysis was used. As candidate independent variables for 
the multivariate models, CPBP (SBP and DBP) and all the variables collected to 
characterize the study sample were considered. Univariate logistic regression 
was used to select the variables that were finally entered in the multivariate 
models (p value <0.2). A priori, quantitative independent variables (i.e., SBP, 
DBP, age and BMI) were entered into the model in their original form. However, 
none of them showed a linear relationship with the dependent variable, when 
linearity was checked. Due to this fact, these quantitative variables were 
converted into categorical variables based on their tertiles (i.e., each variable 
was stratified in 3 groups with similar number of individuals). A second 
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multivariate logistic model was constructed using CP-MUCH, defined by 
daytime ABP only, as the dependent variable. The goodness-of-fit of the models 
was assessed using the Hosmer-Lemeshow test (the model was considered 
acceptable if the test was not statistically significant). A p-value <0.05 was 
considered statistically significant. 
Results 
The final sample of the MEPAFAR study comprised 169 treated hypertensive 
patients; 98 of whom had CPBP <135/85 mmHg. This sub-group of 98 was the 
subject of the present analysis. The general characteristics of the sample are 
shown in table 1.  
CP-MUCH was found in 24 (24.5%) individuals: 11 of whom had uncontrolled 
HBP only; 8 had uncontrolled daytime BP only; and 5 had both home and 
daytime uncontrolled BP. Patients with CP-MUCH presented significantly higher 
CPBP, HBP and ABP than those without the condition; however, none of the 
mean BP values were above the threshold limits (table 1). Among patients with 
CP-MUCH, those with both home and daytime uncontrolled BP (n=5) presented 
the highest SBP figures [128.6 (SD: 6.6) at the pharmacy, 140.0 (SD: 6.4) 
mmHg at home, and 139.6 (SD: 3.4) mmHg by ambulatory monitoring] (figure 
1). 
As shown in table 2 and figure 2, the proportion of individuals with CP-MUCH 
tends to be higher as systolic and diastolic CPBP increases; for example, the 
prevalence of CP-MUCH reached 47% (7 out of 15) in patients with systolic 
CPBP ≥123 mmHg and diastolic CPBP ≥79 mmHg. Based on the univariate 
regression analysis, age, diabetes, and both systolic and diastolic CPBP were 
9 
 
selected as factors to be entered into the multivariate model (table 2). The 
multivariate regression analysis revealed systolic CPBP ≥115 mmHg as an 
independent factor of CP-MUCH [from 115 to 122.9 mmHg: OR=10.74 
(p=0.036); ≥123 mmHg: OR=16.46 (p=0.012); systolic CPBP <115 mmHg as 
the reference]. When only daytime ABP was used to identify CP-MUCH (n=13), 
again, only systolic CPBP was found to be associated [≥123 mmHg: OR=10.85 
(p=0.036); systolic CPBP <115 mmHg as the reference].  
Discussion  
Measurement of BP in community pharmacies is a widespread practice that is 
recommended by several hypertension societies18-20. Nevertheless, some 
caution should be exercised when considering and using this method; 
specifically, when normal figures are obtained, CPBP readings might encourage 
erroneous conclusions about hypertension control in some cases. In fact, in this 
study, CP-MUCH was identified in a quarter of the patients with normal CPBP. 
Ideally, ABPM and/or HBPM would be recommended in all patients with normal 
CPBP; however, this is not feasible or achievable in practice. In light of this, our 
results might assist community pharmacists to identify individuals who are more 
likely to present CP-MUCH and, thus, prioritize the use of the out-of-pharmacy 
BP methods among treated hypertensive patients with normal CPBP.   
Based on the results of the multivariate analysis, CP-MUCH was associated 
with systolic CPBP and should be investigated when systolic figures ≥115 
mmHg are obtained. However, due to the low BP cut-off point, this 
recommendation still encourages a wide use of ABPM and/or HBPM that might 
not be achievable in some cases (for example, a patient’s lack of willingness to 
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monitor BP). Additional results of this study allow identification of certain 
circumstances in which either the prevalence of CP-MUCH or the relevance of 
the situation might be greater. When CP-MUCH was defined by means of 
ABPM only, the multivariate analysis revealed that individuals with systolic 
CPBP ≥123 mmHg are more likely to present CP-MUCH. This is particularly 
noteworthy when it is considered that ABPM is the reference method in the 
management of hypertension. In addition, although diastolic CPBP was not 
associated with CP-MUCH, the prevalence of CP-MUCH increased (across any 
systolic BP strata) as diastolic CPBP was closer to the upper-normal limits (≥79 
mmHg; figure 2). Overall, HBP and ABP figures were not remarkably elevated 
in patients with CP-MUCH (table 1, figure 1). Only individuals with both home 
and daytime uncontrolled BP revealed high SBP figures. Interestingly, 4 out of 
these 5 individuals had systolic CPBP ≥123 mmHg. Based on these 
observations taken together, community pharmacists would be encouraged to 
further assess BP control (using ABPM and/or HBPM) when systolic CPBP 
≥123 mmHg and diastolic CPBP ≥79 mmHg. From a practical perspective, this 
might represent a more feasible approach than considering all the individuals 
with systolic CPBP ≥115 mmHg.  
This study provides original evidence of the factors associated with CP-MUCH, 
which, at first instance, should not be assumed to be the same condition as 
presents in the physician office. This statement is based the results of the 
Palmera study10 in which CPBP and physician office BP inversely classified BP 
control in 34.3% of patients (kappa coefficient for the agreement between 
methods: 0.35). These results suggest that individuals with CP-MUCH would be 
unlikely to be the same individuals as those presenting with MUCH in the 
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physician office. Thus, factors associated with MUCH should be independently 
studied in both of these settings. As a reasonable starting point, our primary 
analysis included and checked many factors that have been previously 
associated with MUCH in the physician office: gender5-7, age5-7, smoking 
status6, clinic BP5-9 (instead of CPBP), BMI5,8, number of antihypertensive drugs 
taken8,9 and diabetes5. In our opinion, other potential factors21 might be taken 
into account in the future, considering also undiagnosed patients and large 
samples. Another interesting subject to be addressed by future research would 
be the reproducibility of CP-MUCH. Nonetheless, while additional evidence is 
generated in other studies, we believe our results will be useful for improving 
the assessment of BP in treated hypertensive patients and for detecting CP-
MUCH. 
According to recent hypertension guidelines15,16, we used a single definition of 
CP-MUCH, combining the results of both HBP and ABP monitoring. On the one 
hand, this represents a more conservative approach, since, theoretically, 
patients with either elevated HBP or elevated daytime ABP require further 
evaluation. On the other hand, most patients with CP-MUCH had only one out-
of-pharmacy BP elevation, thus revealing that both methods are complimentary 
and that incomplete information is obtained when one is used in isolation. It 
should be noted that all patients included in this analysis were adherent to the 
HBPM protocol (4 days; 3 measurements in the morning and 3 in the evening), 
so the minimum number of HBP measures established by international 
guidelines for assessing hypertension was reached22,23. 
The results of this study are constrained by the procedures used for measuring 
BP at the community pharmacy. The measurement approach is supported by 
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the Spanish Society of Hypertension19 and was initially established based on 
guidelines for BP measurement in the clinic24, which recommend taking 
repeated BP measures per visit over at least 2 to 3 visits. In addition, based on 
previous results of this study12,25, the data from the first pharmacy visit and the 
first measurement from each visit were discarded in order to minimize the white-
coat effect. Thus, it seemed reasonable to use the same threshold limits for 
HBP and daytime ABP. This protocol for measuring CPBP follows the 
guidelines and, thus, meets the standards of quality care. Moreover, in our 
opinion, it is simple and might be easily implemented in practice. Finally, it 
should be noted that measuring BP by community pharmacists can be used as 
a first step in assessing BP control in hypertensive treated patients who are not 
willing or capable to monitor either HBP or ABP26. Then, based on measured 
CPBP, pharmacist may recommend to some patients a further BP assessment 
using ABPM and/or HBPM19,23,27.   
In conclusion, CP-MUCH, which affected a quarter of the patients in this study, 
was only associated with systolic CPBP. Further assessment, using ABPM 
and/or HBPM, is recommended in treated hypertensive patients with controlled 
CPBP, but who have systolic figures ≥115 mmHg. A more feasible approach 
however would be to evaluate patients with both systolic CPBP ≥123 mmHg 
and diastolic CPBP ≥79 mmHg. These results may assist in promoting better 
management of hypertension from the community pharmacy. 
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Figure 1. Average blood pressure figures in patients with CP-MUCH. 
 
Legend: 
ABP: ambulatory blood pressure; CPBP: community pharmacy blood pressure; DBP: 





FIGURE 2. Prevalence of CP-MUCH across blood pressure strata in the 
community pharmacy  
 
Legend: 
BP: blood pressure. 
 
